|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country显示文摘AIM To investigate peg-interferon(peg-IFN) and ribavirin(RBV) therapy in Myanmar and to predict sustained virologic response(SVR).METHODS This single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a(180 μg/wk) or alpha-2b(50 to 100 μg as a weight-based dose) and RBV as a weight-based dose(15 mg/kg/d). Treatment duration was 48 wk for genotypes 1 and 6, 24 wk for genotype 2, and 24 or 48 wk for genotype 3 based on rapid virologic response(RVR). Those co-infected with hepatitis B received 48 wk of therapy.RESULTS Overall, SVR was achieved for 82% of patients and the therapy was well tolerated. All patients achieved SVR at equivalent rates regardless of HCV genotype(P = 0.314). Low fibrosis scores(P < 0.001), high baseline albumin levels(P = 0.028) and low baseline viral loads(P = 0.029) all independently predicted SVR. On the other hand, IL-28 B TT and CC genotypes were not found to significantly predict SVR(P = 0.634; P = 0.618). Among those who completed treatment, the occurrence of RVR showed a > 96% positive predictive value for achieving SVR. Treatment duration did not significantly impact the likelihood of achieving SVR for patients infected with genotype 3 HCV(P = 0.371). The most common adverse events were fatigue(71%) and poor appetite(60%). Among patients with genotype 3 HCV, more patients in the 48-wk treatment group required erythropoietin than in the 24-wk treatment group(61.1% vs 49.2%).CONCLUSION SVR rates were high with peg-IFN and RBV therapy in Myanmar. Fibrosis scores, baseline albumin, HCV RNA levels and RVR independently predicted SVR. | Naomi Khaing Than Hlaing Debolina Banerjee Robert Mitrani Soe Htet Arker Kyaw San Win Nyan Lin Tun Zaw Thant Khin Maung Win K Rajender Reddy | 2016 | World Journal of Gastroenterology2016，22，43： | 2 |
| 2 | Frequency of sudden cardiac death and profiles of risk显示文摘 | Interian A Jr Mitrani RM | 1997 | Am J Cardiol1997，80，： | 1 |
| 3 | Frequency of sudden cardiac death and profiles of risk显示文摘 | Myerburg R J Interian A Jr Mitrani R M | 1997 | Am J Cardiol1997，80，5： | 1 |
| 4 | Anorectal manometriccharacteristics in men and women with idiopathic fecalincontinence显示文摘 | Mitrani C’Chun A Desautels S | 1998 | J Clin Gastroenterol1998，26，3： | 1 |
| 5 | Frequency of sudden cardiac death and profiles of risk显示文摘 | Myerburg RJ lnterian AJ Mitrani RM | 1997 | Am J Cardiol1997，80，： | 1 |
| 6 | Posterior implants for distal extension removable prostheses:A retrospective study显示文摘 | Mitrani R Brudvik JS Phillips KM | 2003 | Int J Periodontics Restorative Dent2003，23，4： | 1 |
| 7 | A telemedicine application utilizing DataSocket(R) to remotely track the heart rate variability of patients in a clinical research environment显示文摘 | Atapattu S A Mitrani R D | 2000 | Information Technology Applications in Biomedicine2000，，9： | 1 |
| 8 | Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival 显示文摘 | Jain S Wei J Mitrani LR | 2012 | Breast Cancer Res Treat2012，135，1： | 1 |
| 9 | Regional cardiacsympathetic denervation in patients with ventriculartachycardia in the absence of coronary artery disease显示文摘 | Mitrani RD Klein LS Miles WM | 1993 | JAm Coll Cardiol1993，22，5： | 1 |
| 10 | Spectral expansion solution for a class of Markov models: application andcomparison with the matrix-geometric method 显示文摘 | Mitrani I Chakka R | 1995 | Performance Evaluation1995，23，： | 1 |
| 11 | Eraluation of Pharmacologyicaland device therapy for themanagementof life threatening arrhythmias显示文摘 | Mitrani R Interian JRA | 1999 | Eur Heart J1999，，1： | 1 |
| 12 | Radiofrequency ablatin for atrioventricular node reentrant tachycardia:comparison between fast (anterior) and slow (posterior) pathway ablation显示文摘 | Mitrani RD Klein LS Hackett FK | 1993 | J Am Coll Cardiol1993，21，： | 1 |
| 13 | Evaluation of pharmacological and device therapy for the management of life - threatening arrhythmias显示文摘 | Myerburg R J Mitrani J R A | 1999 | Eur Heart J Supplements1999，1，： | 1 |
| 14 | Limiting field strength and electron swarm coefficients of the CF31-SF6 gas mixture显示文摘 | de Urquijo J Mitrani A Ruiz-Vargas G | 2011 | Jour- nal of Physics D: Applied Physics2011，44，34： | 1 |
| 15 | Limiting field strength and elecaon swarm coefficients of the CF3I-SF6 gas mixture显示文摘 | de Urquijo J Mitrani A RuizVargas G | 2011 | Journal of Physies D: Applied Physics2011，44，34： | 1 |
| 16 | Frequency of sudden cardiac death and profiles of risk显示文摘 | MYERBURG R J INTERIAN A JR MITRANI R M | 1997 | Am J Cardiol1997，，： | 1 |
| 17 | Service center trade-offs between customer impatience and power consumption 显示文摘 | Mitrani I | 2011 | Performance Evaluation2011，68，11： | 1 |
| 18 | Giant ossiningfibroma of the paranasal sinuses 显示文摘 | Mitrani M Remsen K Lawson W | 1988 | Era-Nose Throat J1988，67，18： | 1 |
| 19 | Eraluation ofPharmacologyical, and device therapy for the management oflife threatening arrhythmias显示文摘 | Myerburg RJ Mitrani R Interian JRA | 1999 | EurHeart J1999，，1： | 1 |
| 20 | Pathergy reaction in Behcet's disease: lack of correlation with mucocutaneous manifestations and systemic disease expression显示文摘 | Molad Y Mitrani M | 2000 | Clin Exp Rheumatol2000，18，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员